UBS Group
SCTX

UBS Group’s Scribe Therapeutics Inc SCTX Stock Holding History

UBS Group’s Portfolio SCTX Stock Details SCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.31M Buy
+71,067
New +$1.87M ﹤0.01% 5406

Other funds holding SCTX

Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Menlo Ventures Management
Menlo Ventures Management Menlo Park, California $241M AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

UBS Group's SCTX Position: Q3 2026 in Review

UBS Group opened a new position in Scribe Therapeutics Inc (SCTX) in Q3 2026: 71,067 shares worth $1.31M. The stake represents ﹤0.01% of the portfolio and ranks #5406 among its holdings.

17 funds tracked by Wall St. Rank hold SCTX as of Q3 2026.

  • UBS Group held 71,067 shares of Scribe Therapeutics Inc worth $1.31M as of Q3 2026.
  • Scribe Therapeutics Inc was a new UBS Group position in Q3 2026.
  • Scribe Therapeutics Inc made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #5406 holding.
  • 17 funds tracked by Wall St. Rank held Scribe Therapeutics Inc as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.